Cargando…
High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated im...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328563/ https://www.ncbi.nlm.nih.gov/pubmed/35895743 http://dx.doi.org/10.1371/journal.pone.0272008 |
_version_ | 1784757749253406720 |
---|---|
author | Kadyrova, Irina Yegorov, Sergey Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Akhmaltdinova, Lyudmila Vazenmiller, Dmitriy Stupina, Yelena Kabildina, Naylya Ashimova, Assem Raimbekova, Aigul Turmukhambetova, Anar Miller, Matthew S. Hortelano, Gonzalo Babenko, Dmitriy |
author_facet | Kadyrova, Irina Yegorov, Sergey Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Akhmaltdinova, Lyudmila Vazenmiller, Dmitriy Stupina, Yelena Kabildina, Naylya Ashimova, Assem Raimbekova, Aigul Turmukhambetova, Anar Miller, Matthew S. Hortelano, Gonzalo Babenko, Dmitriy |
author_sort | Kadyrova, Irina |
collection | PubMed |
description | COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated immunity in a multi-ethnic cohort of public university employees in Karaganda, Kazakhstan. Asymptomatic subjects (n = 100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)-reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds. S-IgG and -IgA seropositivity rates among SARS-CoV-2 PCR-negative participants (n = 100) were 42% (95% CI [32.2–52.3]) and 59% (95% CI [48.8–69.0]), respectively, and 64% (95% CI [53.4–73.1]) of the cohort tested positive for at least one of the antibodies. S-IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity, but not with other ethnic minorities present in the cohort, and self-reported history of respiratory illness since March 2020. Overall, SARS-CoV-2 exposure in this cohort was ~15-fold higher compared to the reported all-time national and regional COVID-19 prevalence, consistent with recent studies of excess infection and death in Kazakhstan. Continuous serological surveillance provides important insights into COVID-19 transmission dynamics and may be used to better inform the regional public health response. |
format | Online Article Text |
id | pubmed-9328563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-93285632022-07-28 High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination Kadyrova, Irina Yegorov, Sergey Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Akhmaltdinova, Lyudmila Vazenmiller, Dmitriy Stupina, Yelena Kabildina, Naylya Ashimova, Assem Raimbekova, Aigul Turmukhambetova, Anar Miller, Matthew S. Hortelano, Gonzalo Babenko, Dmitriy PLoS One Research Article COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated immunity in a multi-ethnic cohort of public university employees in Karaganda, Kazakhstan. Asymptomatic subjects (n = 100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)-reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds. S-IgG and -IgA seropositivity rates among SARS-CoV-2 PCR-negative participants (n = 100) were 42% (95% CI [32.2–52.3]) and 59% (95% CI [48.8–69.0]), respectively, and 64% (95% CI [53.4–73.1]) of the cohort tested positive for at least one of the antibodies. S-IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity, but not with other ethnic minorities present in the cohort, and self-reported history of respiratory illness since March 2020. Overall, SARS-CoV-2 exposure in this cohort was ~15-fold higher compared to the reported all-time national and regional COVID-19 prevalence, consistent with recent studies of excess infection and death in Kazakhstan. Continuous serological surveillance provides important insights into COVID-19 transmission dynamics and may be used to better inform the regional public health response. Public Library of Science 2022-07-27 /pmc/articles/PMC9328563/ /pubmed/35895743 http://dx.doi.org/10.1371/journal.pone.0272008 Text en © 2022 Kadyrova et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kadyrova, Irina Yegorov, Sergey Negmetzhanov, Baurzhan Kolesnikova, Yevgeniya Kolesnichenko, Svetlana Korshukov, Ilya Akhmaltdinova, Lyudmila Vazenmiller, Dmitriy Stupina, Yelena Kabildina, Naylya Ashimova, Assem Raimbekova, Aigul Turmukhambetova, Anar Miller, Matthew S. Hortelano, Gonzalo Babenko, Dmitriy High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
title | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
title_full | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
title_fullStr | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
title_full_unstemmed | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
title_short | High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination |
title_sort | high sars-cov-2 seroprevalence in karaganda, kazakhstan before the launch of covid-19 vaccination |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328563/ https://www.ncbi.nlm.nih.gov/pubmed/35895743 http://dx.doi.org/10.1371/journal.pone.0272008 |
work_keys_str_mv | AT kadyrovairina highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT yegorovsergey highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT negmetzhanovbaurzhan highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT kolesnikovayevgeniya highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT kolesnichenkosvetlana highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT korshukovilya highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT akhmaltdinovalyudmila highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT vazenmillerdmitriy highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT stupinayelena highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT kabildinanaylya highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT ashimovaassem highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT raimbekovaaigul highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT turmukhambetovaanar highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT millermatthews highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT hortelanogonzalo highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination AT babenkodmitriy highsarscov2seroprevalenceinkaragandakazakhstanbeforethelaunchofcovid19vaccination |